Burden of prostate cancer in the Middle East: A comparative analysis based on global cancer observatory data

Kearney, Garrett; Chen, Ming‐Hui; Mula‐Hussain, Layth; Skelton, Mac; Eren, Mehmet Fuat; Orio, Peter F.; Nguyen, Paul L.; D'Amico, Anthony V.; Sayan, Mutlay

doi:10.1002/cam4.6689

Cited by 3 publications

(1 citation statement)

References 21 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 79.1% increase in PC incidence is predicted by 2040 [ 1 , 3 ]. The age-standardised incidence rate (ASIR) in the Middle East (ME) region was 10.50 per 100,000 person-years (PY) in 2020, compared with 21.50 per 100,000 PY in Europe and North America [ 4 ]. However, PC incidence in the Middle East and North Africa (MENA) is steadily increasing, which may be explained by acculturation and lifestyle modifications [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Prostate cancer across four countries in the Middle East: a multi-centre, observational, retrospective and prognostic study

El-Karak,

Shamseddine,

Omar

et al. 2024

ecancer Journal

View full text Add to dashboard Cite

Prostate cancer (PC) is the second most prevalent cancer in males, with a steadily increasing incidence in the Middle East (ME). The aim of this study was to capture real-world data on the characteristics, disease progression, and treatment patterns among PC patients in the ME. This was a retrospective, observational, multi-centre study conducted across ten hospitals/research centers in Lebanon, Kingdom of Saudi Arabia, Iraq and Kuwait. Data were abstracted from medical records of 615 male patients who were diagnosed with PC between January 2012 and the site initiation date (December 2018-May 2019) and received at least one PC treatment/intervention. The observation period ranged between 84 and 88 months. Data were collected on demographics, clinical characteristics, time to progression to the subsequent clinical state or therapy (progression from localised/locally advanced PC to castration and to metastatic PC (metastatic castration-sensitive PC (mCSPC) or metastatic castration-resistant PC (mCRPC)), progression from mCSPC to mCRPC, and mCRPC patients’ progression to first subsequent line of therapy), treatment patterns, and mortality. Most patients had localised/locally advanced PC (57.7%), followed by mCSPC (37.4%), and mCRPC (4.1%) at the time of inclusion in the study. Most patients were at tumours, nodes and metastases (TNM) stage IIIa (40.1%) or TNM stage IVb (27.8%) at study entry. Median time to metastatic disease, castration-resistance and next line therapy was 84 months (95% CI: 68–84), 41 months (95% CI: 30–56) and 7 months (95% CI: 0–41), respectively. The mortality rate was 3.6%. Disease progression was most common among patients with mCSPC (35.1%) or mCRPC (14.8%), and treatment discontinuation was most common among patients with mCRPC (36.6% treatments discontinued). The results show that most patients were at an advanced TNM stage at study entry, suggestive of a lack of awareness regarding PC. Disease progression was most common among patients with metastatic disease, reflecting the challenge of treating metastatic disease and highlighting the need for novel treatments.

show abstract

Section: Introductionmentioning

confidence: 99%

Prostate cancer across four countries in the Middle East: a multi-centre, observational, retrospective and prognostic study

El-Karak,

Shamseddine,

Omar

et al. 2024

ecancer Journal

View full text Add to dashboard Cite

show abstract

Prostate cancer presentation and management in the Middle East

Sayan,

Langoe,

Aynaci

et al. 2024

BMC Urol

View full text Add to dashboard Cite

Background Although prostate cancer is a prevalent malignancy worldwide, its clinical presentation and management in the Middle East are not well-documented. This study aims to provide insights into the initial clinical presentation and management of prostate cancer in this region. Methods A retrospective review was conducted on seven institutional databases from six Middle Eastern countries, including Türkiye, Lebanon, Iraq, Syria, Bahrain, and Jordan, to identify patients diagnosed with prostate cancer in 2021. Descriptive analysis was performed on the collected data to provide an overview of the demographic, clinical, and treatment variables. Results A total of 1,136 patients were identified with a median age of 70 (range, 50–84). Most patients (78%) received their prostate cancer diagnosis after presenting with symptoms, as opposed to routine PSA screening. At the time of diagnosis, 35% of men had clinical T3 or T4 disease, 54% with Stage IV disease and 50% with Gleason score ≥ 8. Regarding treatment, 20% of non-metastatic and 22% of metastatic patients received no treatment. Conclusion Most men in this study sought prostate cancer evaluation due to symptoms and were subsequently diagnosed with advanced-stage disease, providing a foundation for future research aimed at understanding the underlying factors behind the observed trends and enabling informed interventions.

show abstract

Prostate Cancer Awareness in the Middle East: A Cross-Sectional International Study

Sayan,

Eren,

Tuac

et al. 2024

JCO Glob Oncol

Self Cite

View full text Add to dashboard Cite

PURPOSE Prostate cancer has emerged as a significant public health challenge in the Middle East, characterized by rising incidence rates and a concerning mortality-to-incidence ratio. Yet, despite these alarming trends, data regarding prostate cancer awareness in the region remain limited. To address this critical knowledge gap, this study investigates prostate cancer awareness within the Middle East. MATERIALS AND METHODS A cross-sectional survey was performed among 5,913 men age 40 years and older across 14 Middle Eastern countries between January 1, 2022, and July 31, 2023. Excluding those with a history of prostate cancer, a validated questionnaire assessed prostate cancer awareness. Data were analyzed using frequencies and percentages for categorical variables, medians and ranges for continuous variables, and Pearson chi-square analysis for relationships between education levels and awareness of prostate cancer. RESULTS The survey achieved a 74.9% response rate, with 4,431 male participants. Regarding prostate cancer awareness, 83.8% of participants had heard of the disease. However, only 31.0% correctly identified it as the most common malignancy in men, and 21.8% believed it affects both sex. Awareness of screening was limited, with just 19.1% recognizing the prostate-specific antigen test's role. Additionally, participants had a pessimistic view, with a mean perception that 75% of patients with prostate cancer die from the disease, rather than from other causes. Higher education levels were associated with significantly increased awareness of prostate cancer ( P < .001). CONCLUSION This study reveals that while general awareness of the disease exists, crucial knowledge deficits regarding risk factors, screening, and prognosis are evident. Addressing these knowledge gaps through culturally tailored education may improve early detection rates, treatment outcomes, and ultimately reduce the burden of prostate cancer in the Middle East.

show abstract

Burden of prostate cancer in the Middle East: A comparative analysis based on global cancer observatory data

Cited by 3 publications

References 21 publications

Prostate cancer across four countries in the Middle East: a multi-centre, observational, retrospective and prognostic study

Prostate cancer across four countries in the Middle East: a multi-centre, observational, retrospective and prognostic study

Prostate cancer presentation and management in the Middle East

Prostate Cancer Awareness in the Middle East: A Cross-Sectional International Study

Contact Info

Product

Resources

About